Kobashigawa J A, Stevenson L W, Brownfield E D, Gleeson M P, Moriguchi J D, Kawata N, Minkley R, Drinkwater D C, Laks H
Division of Cardiology and Cardiothoracic Surgery UCLA School of Medicine, USA.
J Heart Lung Transplant. 1995 Sep-Oct;14(5):963-7.
To avoid the long-term side effects of corticosteroids, corticosteroid-free immunosuppression has been introduced immediately or late (more than 6 months) after heart transplantation. Late corticosteroid weaning may have a higher success rate as patients are selected on the basis of rejection history. Previous reports of HLA-DR mismatching and the long-term metabolic benefits with respect to corticosteroid weaning have been equivocal.
One hundred and one eligible heart transplant recipients receiving triple-drug immunosuppression 6 months from heart transplantation were weaned from prednisone by decreasing the daily prednisone dose by 1 mg each month. Moderate rejection episodes were recorded and after conclusion of the study, HLA-DR mismatching of recipient and donor was reviewed. Serum cholesterol level, body weight, and number of patients receiving blood pressure medications were recorded before and 1 year after corticosteroid weaning.
Successful weaning from corticosteroids was achieved in 82% of patients. Of 31 patients with zero or one HLA-DR mismatch, 30 (97%) were successfully weaned. For those patients more than 1 year after discontinuation of corticosteroids, 67 had more weight loss and a lower serum cholesterol level than 15 patients who were unsuccessful at corticosteroid weaning and dependent on corticosteroids.
Heart transplant recipients can safely be weaned from corticosteroids late after heart transplantation with zero or one HLA-DR mismatch conferring a higher success rate. The long-term metabolic benefits of corticosteroid weaning include a reduction in weight and serum cholesterol.
为避免皮质类固醇的长期副作用,心脏移植后立即或晚期(超过6个月)采用了无皮质类固醇免疫抑制方案。晚期停用皮质类固醇可能成功率更高,因为患者是根据排斥反应史挑选出来的。先前关于HLA - DR错配以及停用皮质类固醇对长期代谢益处的报道并不明确。
101名符合条件的心脏移植受者在心脏移植6个月后接受三联药物免疫抑制治疗,通过每月将泼尼松每日剂量减少1毫克来停用泼尼松。记录中度排斥反应发作情况,研究结束后,回顾受者和供者的HLA - DR错配情况。记录停用皮质类固醇前及1年后的血清胆固醇水平、体重以及接受血压药物治疗的患者人数。
82%的患者成功停用皮质类固醇。在31名HLA - DR错配为零或一个的患者中,30名(97%)成功停用。对于那些停用皮质类固醇超过1年的患者,67名患者的体重减轻更多,血清胆固醇水平低于15名停用皮质类固醇未成功且仍依赖皮质类固醇的患者。
心脏移植后晚期,HLA - DR错配为零或一个的心脏移植受者可以安全地停用皮质类固醇,成功率更高。停用皮质类固醇的长期代谢益处包括体重减轻和血清胆固醇降低。